Bacteriophage Therapy Testing Against Shigella Flexneri in a Novel Human Intestinal Organoid-Derived Infection Model
Overview
Authors
Affiliations
Objective: Enteric bacterial pathogens cause diarrheal disease and mortality at significant rates throughout the world, particularly in children younger than 5 years. Our ability to combat bacterial pathogens has been hindered by antibiotic resistance, a lack of effective vaccines, and accurate models of infection. With the renewed interest in bacteriophage therapy, we sought to use a novel human intestinal model to investigate the efficacy of a newly isolated bacteriophage against Shigella flexneri.
Methods: An S. flexneri 2457T-specific bacteriophage was isolated and assessed through kill curve experiments and infection assays with colorectal adenocarcinoma HT-29 cells and a novel human intestinal organoid-derived epithelial monolayer model. In our treatment protocol, organoids were generated from intestinal crypt stem cells, expanded in culture, and seeded onto transwells to establish 2-dimensional monolayers that differentiate into intestinal cells.
Results: The isolated bacteriophage efficiently killed S. flexneri 2457T, other S. flexneri strains, and a strain of 2457T harboring an antibiotic resistance cassette. Analyses with laboratory and commensal Escherichia coli strains demonstrated that the bacteriophage was specific to S. flexneri, as observed under co-culture conditions. Importantly, the bacteriophage prevented both S. flexneri 2457T epithelial cell adherence and invasion in both infection models.
Conclusions: Bacteriophages offer feasible alternatives to antibiotics for eliminating enteric pathogens, confirmed here by the bacteriophage-targeted killing of S. flexneri. Furthermore, application of the organoid model has provided important insight into Shigella pathogenesis and bacteriophage-dependent intervention strategies. The screening platform described herein provides proof-of-concept analysis for the development of novel bacteriophage therapies to target antibiotic-resistant pathogens.
Development of a therapeutic delivery platform with reduced colonization potential.
Alexander L, Khalid S, Gallego-Lopez G, Astmann T, Oh J, Heggen M Appl Environ Microbiol. 2024; 90(11):e0031224.
PMID: 39480094 PMC: 11577788. DOI: 10.1128/aem.00312-24.
Sulaksono H, Annisa A, Ruslami R, Mufeeduzzaman M, Panatarani C, Hermawan W Int J Nanomedicine. 2024; 19:6201-6228.
PMID: 38911499 PMC: 11193994. DOI: 10.2147/IJN.S455940.
Advancements in understanding bacterial enteritis pathogenesis through organoids.
Wu Z, Liu H, Wang X Mol Biol Rep. 2024; 51(1):512.
PMID: 38622483 DOI: 10.1007/s11033-024-09495-5.
Bacteriophages and Their Host Range in Multidrug-Resistant Bacterial Disease Treatment.
Chung K, Liau X, Tang S Pharmaceuticals (Basel). 2023; 16(10).
PMID: 37895938 PMC: 10610060. DOI: 10.3390/ph16101467.
Functional assays to evaluate antibody-mediated responses against : a review.
Boero E, Vezzani G, Micoli F, Pizza M, Rossi O Front Cell Infect Microbiol. 2023; 13:1171213.
PMID: 37260708 PMC: 10227456. DOI: 10.3389/fcimb.2023.1171213.